The APP/PS1/APOA-I triple-transgenic mouse model exhibits higher levels of serum HDL and improved cerebral amyloid angiopathy and neuroinflammation compared with the APP/PS1 double-transgenic model [112]. This evidence concerns the gene APP and cerebral amyloid angiopathy.